Melanoma
Conditions
Keywords
metastatic melanoma
Brief summary
The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.
Detailed description
This is an open-label, randomized phase II, single institution study comparing administration of a 4-peptide melanoma vaccine alone or post-Ontak, in patients with metastatic melanoma. Treatment: 1. Cohort A: Vaccine alone. Patients will receive immunization with an emulsion of 4 melanoma peptides (250 mcg each)/GM-CSF/Montanide injected intradermally/subcutaneously on day 1. A second vaccination will be given 2 weeks later and a third vaccination 2 weeks after that. Patients will be re-evaluated around week 6 and can continue courses of 3 vaccinations (one every 2 weeks) until disease progression. 2. Cohort B: Ontak plus vaccine. Patients will receive Ontak (18 mcg/kg) intravenously on day -4 for one dose. On day 0, they will receive the first immunization with an emulsion of 4 melanoma peptides (250 mcg each)/GM-CSF/Montanide injected intradermally/subcutaneously. A second vaccination will be given 2 weeks later and a third vaccination 2 weeks after that. Patients will be re-evaluated around week 6 and can continue courses of 3 vaccinations (one every 2 weeks) until disease progression. However, no further Ontak will be given. Duration: Patients may remain on study until disease progression, unacceptable toxicity, patient choice to withdraw, or physician decision to discontinue therapy (due to intervening illness, poor patient compliance, or other situation that would increase patient risk).
Interventions
BIOLOGICAL4-peptide melanoma vaccine
Experimental cancer vaccine given as a shot under the skin once every two weeks
DRUGOntak
A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
Sponsors
Eisai Inc.
University of Chicago
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Melanoma with evidence of metastatic disease * Life expectancy of at least 12 weeks. * Karnofsky performance status index of greater than or equal to 80%. * Adequate hematopoietic, renal, and hepatic function, defined as: * Patient must express HLA-A2 * Tumor biopsy: patient must agree to undergo biopsy of accessible tumor before and after therapy, when feasible, to study tumor cell properties and characteristics of immune cells. * EKG without evidence of arrhythmia or changes that indicate acute ischemia. * Pulse oximetry showing oxygen saturation of at least 90% on room air.
Exclusion criteria
* Significant cardiovascular disease, or cardiac arrhythmia requiring medical intervention. * Pregnant or nursing women. * Biological therapy in the 4 weeks prior to the start of dosing. * Patients with intrinsic immunosuppression, including seropositivity for HIV antibody. * Serious concurrent infection, including active tuberculosis, hepatitis B, or hepatitis C. * Concurrent systemic corticosteroids (except physiologic replacement doses)or other immunosuppressive drugs (eg. cyclosporin A). * Psychiatric illness that may make compliance to the clinical protocol unmanageable or may compromise the ability of the patient to give informed consent. * Active or history of autoimmune disease * Active gastrointestinal bleeding or uncontrolled peptic ulcer disease. * Presence of untreated brain metastases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Response Outcome | 6 weeks | Proportion of Patients With a Best Response of Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD). Response was evaluated every 6 weeks based on Response Evaluation In Solid Tumor (RECIST) version 1.1. Per RECIST v1.1 for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (PD); PD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Vaccine Alone Subjects received vaccine immunization injected intra-dermally or subcutaneously on day 1. The vaccine was an emulsification consisting of 250 mcg each of the following peptides: Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF 125 mcg and Montanide. A second and third vaccination was given at 2 weeks and 4 weeks after the first. If there was no evidence of cancer progression, additional courses of three vaccinations administered at 2 week intervals were administered until disease progression. | 10 |
| Vaccine Plus Ontak Subjects in Vaccine plus Ontak received the same vaccination strategy as Vaccine alone group but additionally received a single dose of denileukin diftitox(18 mcg/kg) 4 days prior to the first vaccine administration. | 7 |
| Total | 17 |
Baseline characteristics
| Characteristic | Vaccine Alone | Vaccine Plus Ontak | Total |
|---|---|---|---|
| Age, Continuous | 57 years | 63 years | 63 years |
| Sex: Female, Male Female | 2 Participants | 1 Participants | 3 Participants |
| Sex: Female, Male Male | 8 Participants | 6 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 10 | 1 / 7 |
| other Total, other adverse events | 10 / 10 | 7 / 7 |
| serious Total, serious adverse events | 2 / 10 | 2 / 7 |
Outcome results
Primary
Clinical Response Outcome
Proportion of Patients With a Best Response of Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD). Response was evaluated every 6 weeks based on Response Evaluation In Solid Tumor (RECIST) version 1.1. Per RECIST v1.1 for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (PD); PD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions
Time frame: 6 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vaccine Alone | Clinical Response Outcome | PR | 1 Participants |
| Vaccine Alone | Clinical Response Outcome | SD | 4 Participants |
| Vaccine Alone | Clinical Response Outcome | PD | 5 Participants |
| Vaccine Plus Ontak | Clinical Response Outcome | PR | 0 Participants |
| Vaccine Plus Ontak | Clinical Response Outcome | SD | 4 Participants |
| Vaccine Plus Ontak | Clinical Response Outcome | PD | 3 Participants |